Viracta Therapeutics to Present at the Jefferies Healthcare Conference
01 6월 2023 - 5:15AM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology
company focused on the treatment and prevention of virus-associated
cancers that impact patients worldwide, today announced that Mark
Rothera, its President and Chief Executive Officer, is scheduled to
present at the Jefferies Healthcare Conference on Wednesday, June
7, 2023, at 3:00 p.m. EDT.
A live webcast of the presentation will be
available on the Investors section of the Viracta website under
"Events and Webcasts" and archived for 90 days.
About Viracta Therapeutics,
Inc.
Viracta is a precision oncology company focused
on the treatment and prevention of virus-associated cancers that
impact patients worldwide. Viracta’s lead product candidate is an
all-oral combination therapy of its proprietary investigational
drug, nanatinostat, and the antiviral agent valganciclovir
(collectively referred to as Nana-val). Nana-val is currently being
evaluated in multiple ongoing clinical trials, including a pivotal,
global, multicenter, open-label Phase 2 basket trial for the
treatment of multiple subtypes of relapsed/refractory Epstein-Barr
virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 trial for the treatment of
EBV+ recurrent or metastatic nasopharyngeal carcinoma and other
advanced EBV+ solid tumors. Viracta is also pursuing the
application of its “Kick and Kill” approach in other virus-related
cancers.
For additional information please
visit www.viracta.com.
Investor Relations Contact:Ashleigh BarretoHead
of Investor Relations & Corporate CommunicationsViracta
Therapeutics, Inc.abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Viracta Therapeutics (NASDAQ:VIRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024